Compare Incyte Corporation (INCY) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs T-Mobile Us Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while T-Mobile Us Inc trades at $148.82 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 8× Incyte Corporation's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and T-Mobile Us Inc for 84 Days on average.
| INCY | TMUS | |
|---|---|---|
Market Cap | $22.85B | $183.76B |
Volume | 1,927,029 | 4,294,650 |
Sector | Health | Media |
52-Week High | $129.93 | $230.06 |
52-Week Low | $83.80 | $161.73 |
Typical Hold Time | 33 Days | 84 Days |
Enterprise Value | $18.35B | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
T-Mobile US (TMUS) trades at $148.58, down 11.36% over 24 hours, reflecting recent market pressure. The stock shows strong fundamental health with revenue growth to $88.31B in 2025 and a net income margin of 11.45%. Analyst consensus is strongly bullish with a $231.10 price target, supported by a 15% dividend hike announced in September 2026. Technical indicators are mixed, with a bearish moving average signal but neutral oscillators, while recent news highlights AI-driven 5G advancements and a joint venture with AT&T and Verizon to expand coverage.
The outlook for TMUS is positive due to robust earnings beats, strategic initiatives, and solid cash flow, though risks include high debt levels and competitive pressures. Investors may find value in its growth trajectory and dividend increases, but should monitor debt management and industry competition closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
